Friday, September 7, 2012
NIH researchers use rodent study to uncover novel approach
New research offers a possible strategy for treating central nervous system diseases, such as brain and spinal cord injury, brain cancer, epilepsy, and neurological complications of HIV. The experimental treatment method allows small therapeutic agents to safely cross the blood-brain barrier in laboratory rats by turning off P-glycoprotein, one of the main gatekeepers preventing medicinal drugs from reaching their intended targets in the brain.
Thursday, September 6, 2012
High mammographic breast density, which is a marker of increased risk of developing breast cancer, does not seem to increase the risk of death among breast cancer patients, according to a study led by Gretchen L. Gierach, Ph.D., of the National Cancer Institute (NCI), part of the National Institutes of Health.
Wednesday, September 5, 2012
International Fetal Alcohol Spectrum Disorders (FASD) Awareness Day, recognized every year on the ninth day of the ninth month, is an important reminder that prenatal alcohol exposure is the leading preventable cause of birth defects and developmental disorders in the United States.
Wednesday, September 5, 2012
Magnetic resonance imaging (MRI) is more effective than electrocardiography (ECG) at identifying "silent" heart attacks, also known as unrecognized myocardial infarctions, according to a study performed by National Institutes of Health researchers and international colleagues.
Wednesday, August 29, 2012
National Institutes of Health scientists have identified how a kind of immature immune cell responds to a part of influenza virus and have traced the path those cells take to generate antibodies that can neutralize a wide range of influenza virus strains. Study researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, were led by Gary Nabel, M.D., Ph.D., director of NIAID’s Vaccine Research Center. Their findings appear online in advance of print in Nature.
Wednesday, August 29, 2012
Scientists have found that calorie restriction — a diet comprised of approximately 30 percent fewer calories but with the same nutrients of a standard diet — does not extend years of life or reduce age-related deaths in a 23-year study of rhesus monkeys. However, calorie restriction did extend certain aspects of health. The research, conducted by scientists at the National Institute on Aging (NIA) at the National Institutes of Health, is reported in the August 29, 2012 online issue of Nature.
Monday, August 27, 2012
Scientists have known for decades that cancer cells use more glucose than healthy cells, feeding the growth of some types of tumors. Now, a team that includes researchers from the National Institutes of Health's new National Center for Advancing Translational Sciences (NCATS) has identified compounds that delay the formation of tumors in mice, by targeting a key enzyme that governs how cancer cells use glucose and its metabolites.
Wednesday, August 22, 2012
For six months last year, a deadly outbreak of antibiotic-resistant bacteria kept infection-control specialists at the National Institutes of Health’s Clinical Center in a state of high alert. A New York City patient carrying a multi-drug resistant strain of Klebsiella pneumoniae, a microbe frequently associated with hospital-borne infections, introduced the dangerous bacteria into the 243-bed research hospital while participating in a clinical study in the summer of 2011.
Friday, August 3, 2012
Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent’s underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.
Wednesday, August 1, 2012
Researchers at the National Institutes of Health have found evidence that a unique type of immune cell contributes to multiple sclerosis (MS). Their discovery helps define the effects of one of the newest drugs under investigation for treating MS — daclizumab — and could lead to a new class of drugs for treating MS and other autoimmune disorders.
